| Industry | 卫生和社会工作业 | ||||||||||||||||||||||||
| Company Introduction | 新里程健康科技集团股份有限公司(简称“新里程股份”，证券代码：002219)是由新里程健康集团有限公司(简称“新里程健康集团”)控股的A股上市公司。新里程股份前身为恒康医疗集团股份有限公司，于2008年3月登陆A股，原为中医药生产商，2013年1月收购第一家医院，开始进入医疗行业，现已成为涵盖医疗服务、药品制造等业务领域的医疗健康产业集团。 在医疗服务领域，新里程股份推进以区域医疗中心为战略的医疗机构布局，打造以三甲综合医院为依托、“综合总院+专科分院” 的“1+N”创新服务模式，聚焦肿瘤、心血管、脑血管、骨科等老年化疾病。目前，新里程股份已在辽宁、河南、江苏、江西、四川分别成立五大区域医疗中心，拥有4家三级医院、7家二甲医院，床位数达万余张。 在药品制造领域，新里程股份以药品制造为基础产业，拥有以“独一味”品牌为核心的系列中成药、化药及生物大分子药物。独一味制药是中国驰名商标，拥有36个国家批号。 新里程股份秉承“让人人享有更美好的健康服务”的使命，将不断通过技术、人才、资金、资源投入，将下属医院打造成为区域领先的医疗服务机构，形成具有竞争优势的医疗品牌；以“独一味”为平台，整合上下游产业链、布局健康消费产品、整合优质同行等，做大做强中药板块，实现品牌创新和内涵升级。 | ||||||||||||||||||||||||
| Main Business | 医疗服务与医药 | ||||||||||||||||||||||||
| Legal Representative | 林杨林 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | -- | ||||||||||||||||||||||||
| Solicitors | 国浩律师（上海）事务所 | ||||||||||||||||||||||||
| Auditors | 瑞华会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 010-85235985 | ||||||||||||||||||||||||
| Fax No | 010-85235985 | ||||||||||||||||||||||||
| Website | www.njhtg.com | ||||||||||||||||||||||||
| dongshiban@njhtg.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 06/03/2008 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.009 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 0.644 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 8.115B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |